Compare INTA & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTA | ANIP |
|---|---|---|
| Founded | 2000 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2021 | 1999 |
| Metric | INTA | ANIP |
|---|---|---|
| Price | $36.25 | $82.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $41.43 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 800.4K | 256.0K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 48.89 | ★ 419.23 |
| EPS | N/A | ★ 2.32 |
| Revenue | ★ $504,120,000.00 | $206,547,000.00 |
| Revenue This Year | $15.91 | $21.01 |
| Revenue Next Year | $13.78 | $17.59 |
| P/E Ratio | ★ N/A | $64.55 |
| Revenue Growth | ★ 17.09 | 2.47 |
| 52 Week Low | $19.01 | $70.15 |
| 52 Week High | $47.93 | $99.50 |
| Indicator | INTA | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Intapp Inc is a provider of industry-specific, cloud-based software solutions for the professional and financial services industry. It empowers private capital, legal, accounting, and consulting firms with the technology needed to meet rapidly changing client, investor, and regulatory requirements. Geographically, it derives a majority of its revenue from the United States and also has a presence in the United Kingdom and the Rest of the world.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.